Evidence map›Paper›PMID 40558274›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

PTEN Mutations Associated with Increased Recurrence and Decreased Survival in Patients with Prostate Cancer Spinal Metastasis.

Albert Antar, Yuanxuan Xia, Abdel-Hameed Al-Mistarehi, Pritika Papali, Melanie Alfonzo Horowitz, Shreya Sriram, Shahab Aldin Sattari, Carly Weber-Levine, Sushanth Neerumalla, Benjamin Z Mendelson and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Albert AntarSchool of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.ORCID 0000-0002-3169-8873
Yuanxuan XiaSchool of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.ORCID 0000-0001-6152-8392
Abdel-Hameed Al-MistarehiSchool of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.ORCID 0000-0003-4713-8536
Pritika PapaliSchool of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
Melanie Alfonzo HorowitzSchool of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
Shreya SriramSchool of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
Shahab Aldin SattariSchool of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
Carly Weber-LevineSchool of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.ORCID 0000-0003-2057-8419
Sushanth NeerumallaSchool of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.ORCID 0009-0007-9561-8688
Benjamin Z MendelsonSchool of Medicine, West Virginia University, Morgantown, WV 26506, USA.ORCID 0009-0002-4971-295X
Sang LeeSchool of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.ORCID 0000-0001-5942-8309
Kristin J RedmondSchool of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
Ali BydonSchool of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
Timothy F WithamSchool of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
Nicholas TheodoreSchool of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.ORCID 0000-0001-5355-2683
Daniel LubelskiSchool of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.ORCID 0000-0002-9403-9509

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionProstate cancer with spinal metastases (PCSM) is associated with high morbidity and mortality. The impact of biomarkers on the prognosis of spinal metastases, however, remains unclear.

objectiveThis study explored associations between potential biomarkers, treatment modalities, survival, and neurological outcomes in PCSM patients.

methodsWe conducted a retrospective analysis of 68 patients as part of a neurosurgical cohort with PCSM at a comprehensive cancer center from 2013 to 2023, examining the influence of potential biomarkers, treatment modalities, and demographics on prognosis. The primary outcomes were the identification of biomarkers, overall survival (OS) in years, survival after spinal metastasis in years, spinal metastasis recurrence, and postoperative neurological outcomes via Frankel scores.

resultsAll the patients (n = 68) had adenocarcinoma, and the median age was 69 years. The mortality rate was 66% with a median OS of 6 years. Seventy-two biomarkers were identified. An accelerated failure time model (AFT) showed that radiotherapy to the prostate increased the OS (TR = 1.805,

conclusions

Indexed as

Neoplasm Recurrence, LocalProstatic NeoplasmsPTEN PhosphohydrolaseSpinal NeoplasmsAgedAged, 80 and overBiomarkers, TumorHumansMaleMiddle AgedMutationPrognosisRetrospective StudiesBiomarkers, TumorPTEN PhosphohydrolasePTEN protein, humangenetic biomarkersmalignancymetastasismortalitymotorprostate cancersensoryspine

Identifiers

PMID40558274
PMCPMC12192451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.